Clinical Trial Update: Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of chemotherapy with alemtuzumab in relapsed or refractory acute lymphoblastic leukemia was terminated, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Acute Lymphoblastic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2014-05-23